TAT polyclonal antibody
Product Specifications
Background
This nuclear gene encodes a mitochondrial protein tyrosine aminotransferase which is present in the liver and catalyzes the conversion of L-tyrosine into p-hydroxyphenylpyruvate. Mutations in this gene cause tyrosinemia (type II, Richner-Hanhart syndrome), a disorder accompanied by major skin and corneal lesions, with possible mental retardation. A regulator gene for tyrosine aminotransferase is X-linked.
CAS Number
9007-83-4
Structure Composition
1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2
Product Name Alternative
TAT
Swiss Prot
P17735
Reactivity
Human, Mouse, Rat
Immunogen
Recombinant fusion protein of human TAT (NP_000344.1) .
Conjugation
Unconjugated
Applications
WB
Dilution
WB,1:500 - 1:2000
Purity
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .
Modification
Unmodification
Molecular Weight
55kDa
Storage Conditions
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Notes
For research use only, not for use in diagnostic procedure.
Specificity
Polyclonal Antibodies
Host or Source
Rabbit
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TE21356B 1 Piece
Classic 14 boxes 32mm, 501x140x140mm, w/locking rod, B9
Sign In for Pricing
View Details MBS2097357-01 0.01 mg
OVA Conjugated Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF)
Sign In for Pricing
View Details MBS2097357-02 0.05 mg
OVA Conjugated Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF)
Sign In for Pricing
View Details MBS2097357-03 0.1 mg
OVA Conjugated Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF)
Sign In for Pricing
View Details MBS2097357-04 0.2 mg
OVA Conjugated Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF)
Sign In for Pricing
View Details